GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach

Acta Diabetologica

Volumn 52, Issue 6, 2015, Pages 1129-1133

  Crisci, Isabella ^a   Aragona, Michele ^a   Politi, Konstantina Savvina ^a   Daniele, Giuseppe ^a   Del Prato, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Continuous glucose monitoring; Glycemic variability; Insulin pump therapy; Liraglutide; Type 1 diabetes

Indexed keywords

INSULIN ASPART; INSULIN LISPRO; LIRAGLUTIDE; PLACEBO; ANTIDIABETIC AGENT; C PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NAUSEA; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION; AGED; AGONISTS; ANALYSIS; BODY MASS; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 1; HYPOGLYCEMIA; MIDDLE AGED;

ADULT; AGED; AREA UNDER CURVE; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED;

EID: 84945461146     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-015-0800-6     Document Type: Article

References (22)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38:140–149
2. Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17:819–837
3. Bruttomesso D, Fongher C, Silvestri B, Barberio S, Marescotti MC, Iori E, Valerio A, Crazzolara D, Pianta A, Tiengo A, Del Prato S (2001) Combination of continuous subcutaneous infusion of insulin and octreotide in Type 1 diabetic patients. Diab Res Clin Pract 51:97–105
4. Kielgast U, Holst JJ, Madsbad S (2009) Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists. Curr Diabetes Rev 5:266–275
5. Kuhaydiya ND, Malik R, Bellini NJ et al (2013) Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. EndocrPract 19:963–967
6. Harrison LB, Mora PF, Clark GO, Lingvay I (2013) Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs. J Investig Med 61:40–44
7. Varanasi A et al (2011) Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 165:77–84
8. Kumar KVH, Shaikh A, Prusty P (2013) Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diab Res Clin Pract 100:55–58
9. Rorther KL, Spain LM, Wesley RA et al (2009) Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care 32:2251–2257
10. Traina AN, Lull ME, Hui AC, Zahorian TM, Lyons-Patterson J (2014) Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy. Can J Diabets 38:269–272
11. Kielgast U, Holst JJ, Madsbad S (2011) Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta-cell function. Diabetes 60:1599–1607
12. Sarkar G, Alattar M, Brown RJ et al (2014) Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care 37:666–670
13. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB (2013) Glucagon like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 173:534–539
14. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141:150–156
15. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC (2013) Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62:2595–2604
16. Halfdanarson TR, Pannala R (2013) Incretins and risk of neoplasia. BMJ 346:f3750
17. Faillie JL, Babai S, Crépin S, Bres V, Laroche ML, Le Louet H, Petit P, Montastruc JL, Hillaire-Buys D, French Pharmacovigilance Centers Network (2014) Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. Acta Diabetol 51:491–497
18. Bonner-Weir S, In’t Veld PA, Weir GC (2014) Reanalysis of sftudy of pancreatic effects of incretin therapy: methodological deficiencies. Diabetes Obes Metab 16:661–666
19. Harja E, Skyler JS (2013) An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology. Diabetes Technol Ther 15:609–618
20. Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, Rosebraugh C (2014) Pancreatic safety of incretin - based dugs—FDA and EMA assessment. N Engl J Med 370:794–797
21. Fiorentino TV, Owston M, Abrahamiam G, La Rosa S, Marando A, Prengo C, Di Cairano ES, Finzi G, Capella C, Sessa F, Casiraghi F, Paez A, Adivi A, Davalli A, Fiorina P, Guardado Mendoza R, Comuzzie AG, Sharp M, DeFronzo RA, Halff G, Dick EJ, Folli F (2015) Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates. Am J Pathol 185:139–150
22. Dejgaard TF, Knop FK, Tamow L, Frandsen CS, Hansen TS, Almdal T, Holst JJ, Madsbad S, Andersen HU (2015) Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomized, double-blind, placebo-controlled study: the Lira-1 study. BMJ Open 5:e007791